title: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
abstract: OBJECTIVE
  In a phase II trial we investigated fludarabine phosphate (FAMP) as therapy for patients with relapsed lymphoma to determine its effectiveness and toxicity in this disease.
  
  
  METHODS
  The 67 assessable patients had a median age of 56 years and had received a median of three chemotherapy regimens before treatment with FAMP. The starting dose was 25 mg/m2 administered intravenously over 30 minutes daily for 5 days every 3 to 4 weeks.
  
  
  RESULTS
  High response rates were observed for follicular small cleaved-cell lymphoma (FSCCL) (62%), follicular mixed small- and large-cell lymphoma (80%), and follicular large-cell lymphoma (FLCL) (100%). Responses also occurred in small lymphocytic lymphoma (SLL) (33%), transformed lymphoma (33%), mycosis fungoides (40%), and Hodgkin's disease (25%). No responses were observed in other intermediate- or high-grade lymphomas (N = 20). Overall, there were five patients with a complete response, 23 patients with a partial response, and an overall response rate of 37%. Toxicity was primarily hematologic and infectious. No significant gastrointestinal, hepatic, renal, or neurologic toxicity occurred.
  
  
  CONCLUSIONS
  We conclude that FAMP has major activity in follicular lymphoma. Fundamental research is needed to understand this differential efficacy in low-grade lymphoma yet lack of efficacy in intermediate- and high-grade lymphoma. Clinical investigations should be done using FAMP in varying dose schedules and in combination regimens.
authors.affiliation: Department of Hematology, University of Texas, M.D. Anderson Cancer Center, Houston.
authors.forename: J R
authors.initials: JR
authors.lastname: Redman
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
authors.forename: W S
authors.initials: WS
authors.lastname: Velasquez
authors.forename: P
authors.initials: P
authors.lastname: McLaughlin
authors.forename: F B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: F
authors.initials: F
authors.lastname: Swan
authors.forename: M A
authors.initials: MA
authors.lastname: Rodriguez
authors.forename: W K
authors.initials: WK
authors.lastname: Plunkett
authors.forename: M J
authors.initials: MJ
authors.lastname: Keating
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate